Zacks Research Downgrades Pelthos Therapeutics (NYSEAMERICAN:PTHS) to Strong Sell

Pelthos Therapeutics (NYSEAMERICAN:PTHS) was downgraded by stock analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a report released on Wednesday, Zacks reports.

Separately, Oppenheimer dropped their target price on shares of Pelthos Therapeutics from $66.00 to $64.00 and set an “outperform” rating on the stock in a report on Friday, August 14th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $55.40.

Pelthos Therapeutics Trading Down 2.3%

Shares of Pelthos Therapeutics stock opened at $20.50 on Wednesday. The stock has a market cap of $78.52 million, a P/E ratio of -0.94 and a beta of 3.07. The company has a quick ratio of 1.31, a current ratio of 1.98 and a debt-to-equity ratio of 3.40. Pelthos Therapeutics has a 12-month low of $18.19 and a 12-month high of $37.50. The business’s 50 day moving average is $24.40 and its 200-day moving average is $25.18.

Pelthos Therapeutics (NYSEAMERICAN:PTHS) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($6.62) EPS for the quarter. Pelthos Therapeutics had a negative net margin of 165.24% and a negative return on equity of 204.71%. The firm had revenue of $15.60 million during the quarter. Equities research analysts predict that Pelthos Therapeutics will post -15.22 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Pelthos Therapeutics

A hedge fund recently raised its stake in Pelthos Therapeutics stock. Pale Fire Capital SE grew its stake in Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) by 59.5% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 12,919 shares of the company’s stock after purchasing an additional 4,819 shares during the quarter. Pale Fire Capital SE owned approximately 0.38% of Pelthos Therapeutics worth $271,000 as of its most recent SEC filing. 77.96% of the stock is owned by hedge funds and other institutional investors.

About Pelthos Therapeutics

Pelthos Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for pain management. The company’s work is centered on addressing unmet needs in the treatment of acute and chronic pain, including the development of potential alternatives to traditional opioid-based medicines.

Pelthos Therapeutics is advancing investigational drug candidates through preclinical and clinical development. As with other clinical-stage biotechnology companies, its products remain subject to testing and regulatory review, and there is no assurance that any candidate will receive approval or become commercially available.

Publicly available information about the company’s specific product pipeline, operating history, geographic reach and leadership is limited.